Novo-Nordisk A/S (NVO) Stock Rating

Novo Nordisk, headquartered in Denmark, is the world's leading provider of diabetes care products and holds roughly one-third of the global branded diabetes treatment market. It develops and sells human and modern insulins, injectable diabetes therapies including GLP-1 treatments, oral antidiabetic agents, and obesity treatments, plus a biopharmaceutical segment (under 10% of revenue) focused on protein therapies for hemophilia and other disorders.